Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance

Enhabit Reports Fourth Quarter Results and Issues Full-Year 2024 Guidance

March 06, 2024 | Last Trade: US$7.46 0.19 2.61

NYSE: EHAB

Healthcare

Healthcare Services

Financial Results

VISIT WEBSITE

Company to host a conference call tomorrow, March 7, 2024, at 10 A.M. EST

DALLAS / Mar 06, 2024 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the fourth quarter ended December 31, 2023.

“Persistent focus on our Company’s strategies drove our positive fourth quarter results,” said Enhabit’s President and Chief Executive Officer Barb Jacobsmeyer. “Payor innovation success, including the finalization of another new national contract, continued success with our people strategy and strong performance in our quality outcomes are but a few of our high points for the end of 2023 and our start to 2024. We are excited about our future and our ability to meet the growing demand for home health and hospice services.”

SUMMARY PERFORMANCE - CONSOLIDATED

Net service revenue of $260.6 million
Net loss attributable to Enhabit, Inc. of $6.4 million
Adjusted EBITDA of $25.2 million
Loss per share of $0.13
Adjusted earnings per share of $0.06

RECENT COMPANY HIGHLIGHTS

Strong growth in home health Medicare Advantage admissions with non-episodic admissions up 34.2% driving total admission growth of 3.9% year over year
Continued payor innovation progress with 11 new Medicare Advantage agreements negotiated during the fourth quarter
- Added one new national advanced episodic agreement effective January 1, 2024
- 25% of non-episodic visits now in payor innovation contracts at improved rates
Home health cost per visit flat year over year
30-day hospitalization readmission rate in home health 20.5% better than national average
Sequential growth in hospice average daily census
Hospice cost per day decreased to $76 after stabilizing at $77 for the prior three quarters
53.2% better than the national average for hospice patient visits in the last days of life
Continued success in recruitment and retention with a 21.5% increase in full-time nursing candidate pool year over year resulting in 119 net new full-time home health nursing hires in the fourth quarter
Opened one home health and one hospice de novo location in the fourth quarter

FINANCIAL RESULTS

Consolidated

*($ in millions, except per share data)*	Q4										*'23 vs. '22*
	2023					2022					*'23 vs. '22*
Home health net service revenue	$			209.5		$			215.8		(2.9	)%
Hospice net service revenue				51.1					47.4		7.8	%
Total net service revenue	$			260.6		$			263.2		(1.0	)%

	% of Revenue					% of Revenue
Cost of services	51.2	%	$	133.5		50.6	%	$	133.3		0.2	%
Gross margin	48.8	%		127.1		49.4	%		129.9		(2.2	)%
General and administrative expenses	38.9	%		101.4		38.0	%		100.0		1.4	%
Total operating expenses	90.1	%	$	234.9		88.6	%	$	233.3		0.7	%
Other income				—					0.9
Net income attributable to noncontrolling interests				0.5					0.5
Adjusted EBITDA	$			25.2		$			30.3		(16.8	)%
*Adjusted EBITDA margin*				*9.7*	%				*11.5*	%
Impairment of goodwill	$			—		$			(109.0	)	N/A
Net loss attributable to Enhabit, Inc.	$			(6.4	)	$			(95.2	)	93.3	%
Reported diluted EPS	$			(0.13	)	$			(1.91	)	93.2	%
Adjusted EPS	$			0.06		$			0.17		(64.7	)%

The continued shift to more non-episodic admissions in home health impacted consolidated revenue and Adjusted EBITDA by approximately $8 million, net of the impact from improved pricing of payor innovation contracts.

SEGMENT RESULTS

Home Health

*($ in millions)*	Q4						*'23 vs. '22*
		2023			2022		*'23 vs. '22*
Net service revenue	$	209.5		$	215.8		(2.9	)%
Cost of services		109.4			109.0		0.4	%
Gross margin		47.8	%		49.5	%
General and administrative expenses	$	59.3		$	60.0		(1.2	)%
Other income	$	—		$	(0.9	)	(100.0	)%
Equity earnings / noncontrolling interest	$	0.5		$	0.5		—	%
Adjusted EBITDA	$	40.3		$	47.2		(14.6	)%
% Adj. EBITDA margin		19.2	%		21.9	%
Operational metrics (Actual Amounts)
Starts of care
Episodic admissions		31,243			34,572		(9.6	)%
Non-episodic admissions		20,764			15,476		34.2	%
Total admissions		52,007			50,048		3.9	%
Same-store total admissions growth							3.2	%
Episodic recertifications		22,849			25,279		(9.6	)%
Non-episodic recertifications		9,179			7,104		29.2	%
Total recertifications		32,028			32,383		(1.1	)%
Same-store total recertifications growth							(1.7	)%
Total starts of care		84,035			82,431		1.9	%
Completed episodes		54,108			60,250		(10.2	)%
Revenue per episode	$	2,924		$	2,958		(1.1	)%
Visits per episode		14.3			14.3		—	%
Total visits		1,162,385			1,159,420		0.3	%
Non-episodic visits		387,055			297,350		30.2	%
Cost per visit	$	92		$	92		—	%

The year-over-year decrease in revenue and Adjusted EBITDA was due primarily to the continued payor mix shift to more non-episodic admissions (approximately $8 million).

Non-episodic admissions grew 34.2% in the quarter, driving total admission growth of 3.9% year over year. Revenue per episode decreased year over year primarily due to patient mix. Cost per visit remained flat year over year as the reduction in nursing contract labor offset the impact of merit and market increases.

Hospice

*($ in millions)*	Q4						'23 vs. '22
		2023			2022		'23 vs. '22
Net service revenue	$	51.1		$	47.4		7.8	%
Cost of services		24.0			24.3		(1.2	)%
Gross margin		53.0	%		48.7	%
General and administrative expenses	$	15.4		$	17.5		(12.0	)%
Equity earnings / noncontrolling interest	$	—		$	—
Adjusted EBITDA	$	11.7		$	5.6		108.9	%
% Adj. EBITDA margin		22.9	%		11.8	%
Operational metrics (Actual Amounts)
Total admissions		2,872			2,915		(1.5	)%
Same-store total admissions growth							(3.8	)%
Patient days		315,870			330,102		(4.3	)%
Discharged average length of stay		102			110		(7.3	)%
Average daily census		3,433			3,588		(4.3	)%
Revenue per day	$	162		$	144		12.5	%
Cost per day	$	76		$	74		2.7	%

Net service revenue increased year over year primarily due to an increase in revenue per day. Revenue per day increased primarily due to changes in our estimated recoverability of net service revenue and increased Medicare reimbursement rates.

Adjusted EBITDA increased year over year primarily due to increased revenue per day and a reduction in general and administrative expenses. Cost per day increased year over year primarily due to increased labor costs resulting from the implementation of the new case management staffing model, including costs associated with dedicated on-call and triage nurses. General and administrative expenses decreased year over year primarily due to reduced headcount at hospice branch locations resulting from implementation of the case management staffing model.

GUIDANCE

The Company is providing full-year 2024 guidance as follows:

Full-year 2024		Guidance
*Net Service Revenue*		between $1,076 and $1,102 million
*Adjusted EBITDA*		between $98 and $110 million
*Adjusted EPS*		between $0.12 and $0.43

For additional considerations regarding the Company’s 2024 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com.

CONFERENCE CALL INFORMATION

The Company will host an investor conference call at 10 a.m. EST on March 7, 2024, to discuss its results for the fourth quarter of 2023. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/272381846. Following the call, a replay will be available at Enhabit’s investor website.

ABOUT ENHABIT HOME HEALTH & HOSPICE

Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what’s possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 110 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

OTHER INFORMATION

Note regarding presentation and reconciliation of non-GAAP financial measures

The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, and Adjusted free cash flow. See “Reconciliations of Non-GAAP Financial Measures” for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies.

The Company is unable to reconcile the guidance for Adjusted EBITDA and Adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

Note regarding presentation of same-store comparisons

The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.

Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited)
	Three Months Ended December 31,						For the Year Ended December 31,
		2023			2022			2023			2022
	(In Millions, Except Per Share Data)
Net service revenue	$	260.6		$	263.2		$	1,046.3		$	1,071.1
Cost of service, excluding depreciation and amortization		133.5			133.3			535.6			525.6
General and administrative expenses		114.5			104.6			441.6			414.9
Depreciation and amortization		7.7			8.3			30.9			33.0
Impairment of goodwill		—			109.0			85.8			109.0
Operating income (loss)		4.9			(92.0	)		(47.6	)		(11.4	)
Interest expense and amortization of debt discounts and fees		12.3			8.7			43.0			15.0
Other income		—			(0.9	)		(0.2	)		(0.9	)
Loss before income taxes and noncontrolling interests		(7.4	)		(99.8	)		(90.4	)		(25.5	)
Income tax (benefit) expense		(1.5	)		(5.1	)		(11.4	)		12.8
Net loss		(5.9	)		(94.7	)		(79.0	)		(38.3	)
Less: Net income attributable to noncontrolling interests		0.5			0.5			1.5			2.1
Net loss attributable to Enhabit, Inc.	$	(6.4	)	$	(95.2	)	$	(80.5	)	$	(40.4	)

Weighted average common shares outstanding:
Basic		50.0			49.7			49.9			49.7
Diluted		50.0			49.8			49.9			49.7

Loss per common share:
Basic loss per share attributable to Enhabit, Inc. common stockholders	$	(0.13	)	$	(1.92	)	$	(1.61	)	$	(0.81	)
Diluted loss per share attributable to Enhabit, Inc. common stockholders	$	(0.13	)	$	(1.91	)	$	(1.61	)	$	(0.81	)

Enhabit, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited)
	December 31, 2023		December 31, 2022
	(In Millions)
Assets
Current assets:
Cash and cash equivalents	$	27.4	$	22.9
Restricted cash		2.4		4.3
Accounts receivable, net of allowances		164.7		149.6
Income tax receivable		3.0		11.4
Prepaid expenses and other current assets		12.6		23.6
Total current assets		210.1		211.8
Property and equipment, net		19.0		20.4
Operating lease right-of-use assets		57.5		42.0
Goodwill		1,061.7		1,144.8
Intangible assets, net		80.0		102.6
Other long-term assets		5.3		5.2
Total assets	$	1,433.6	$	1,526.8
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt	$	22.5	$	23.1
Current portion of operating lease liabilities		11.8		14.0
Accounts payable		7.6		3.8
Accrued payroll		38.5		35.5
Refunds due patients and other third-party payors		8.2		8.3
Accrued medical insurance		8.4		7.5
Other current liabilities		40.7		40.7
Total current liabilities		137.7		132.9
Long-term debt, net of current portion		530.1		560.0
Long-term operating lease liabilities, net of current portion		45.7		28.1
Deferred income tax liabilities		17.1		28.6
Other long-term liabilities		1.3		1.9
		731.9		751.5
Commitments and contingencies
Redeemable noncontrolling interests		5.0		5.2
Stockholders’ equity:
Total Enhabit, Inc. stockholders’ equity		669.7		741.7
Noncontrolling interests		27.0		28.4
Total stockholders’ equity		696.7		770.1
Total liabilities and stockholders’ equity	$	1,433.6	$	1,526.8

Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (Unaudited)
	For the Year Ended December 31,
		2023			2022
	($ in millions)
Cash flows from operating activities:
Net loss	$	(79.0	)	$	(38.3	)
Adjustments to reconcile net loss to net cash provided by operating activities—
Depreciation and amortization		30.9			33.0
Amortization of debt related costs		2.1			0.6
Impairment of goodwill		85.8			109.0
Stock-based compensation		8.9			9.2
Deferred tax benefit		(11.6	)		(4.3	)
Other, net		(0.4	)		0.1
Changes in assets and liabilities, net of acquisitions —
Accounts receivable, net of allowances		(14.6	)		21.6
Prepaid expenses and other assets		19.1			(27.5	)
Accounts payable		3.8			0.2
Accrued payroll		3.0			(31.0	)
Other liabilities		0.4			7.5
Net cash provided by operating activities		48.4			80.1
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired		(2.8	)		(36.3	)
Purchases of property and equipment, including capitalized software costs		(3.5	)		(7.1	)
Other		1.0			1.1
Net cash used in investing activities		(5.3	)		(42.3	)
Cash flows from financing activities:
Principal borrowings on term loan		—			400.0
Principal payments on debt		(20.0	)		(10.0	)
Borrowings on revolving credit facility		—			190.0
Payments on revolving credit facility		(10.0	)		—
Principal payments under finance lease obligations		(3.4	)		(5.0	)
Debt issuance costs		(3.2	)		(4.7	)
Distributions paid to noncontrolling interests of consolidated affiliates		(3.2	)		—
Contributions from Encompass		—			59.8
Distributions to Encompass		—			(654.9	)
Contributions from noncontrolling interests of consolidated affiliates		—			7.4
Other		(0.7	)		(1.2	)
Net cash used in financing activities		(40.5	)		(18.6	)
Increase in cash, cash equivalents, and restricted cash		2.6			19.2
Cash, cash equivalents, and restricted cash at beginning of year		27.2			8.0
Cash, cash equivalents, and restricted cash at end of year	$	29.8		$	27.2

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Diluted Earnings Per Share to Adjusted Earnings Per Share
	Three Months Ended December 31,						Year Ended December 31,
		2023			2022			2023			2022
Diluted earnings per share, as reported	$	(0.13	)	$	(1.91	)	$	(1.61	)	$	(0.81	)
Adjustments, net of tax:
Impairment of goodwill		—			1.91			1.50			1.91
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾		0.18			0.05			0.32			0.14
Income tax adjustments⁽²⁾		0.01			0.12			0.02			0.12
Adjusted earnings per share⁽³⁾	$	0.06		$	0.17		$	0.22		$	1.36

(1)	Unusual or nonrecurring items in Q4 2023 include costs associated with nonroutine litigation, the strategic review process and restructuring activities; FY 2023 include costs associated with nonroutine litigation, restructuring activities, one-time standalone transition costs, shareholder activism and the strategic review process; in 2022, these items include one-time standalone transition costs and costs associated with nonroutine litigation.
(2)	Income tax adjustments include revisions to the estimates of tax balances as of the Separation date and the effect of permanent book-tax differences attributable to stock-based compensation.
(3)	Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share
	Three Months Ended December 31,
	2023
				Adjustments
	As Reported			Unusual or nonrecurring items that are not typical of ongoing operations			Income Tax Adjustments⁽³⁾		As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA⁽¹⁾	$	25.2		$	—		$	—	$	25.2
Interest expense and amortization of debt discounts & fees		(12.3	)		—			—		(12.3	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽²⁾		(11.4	)		11.4			—		—
Depreciation and amortization		(7.7	)		—			—		(7.7	)
Stock-based compensation		(1.7	)		—			—		(1.7	)
Net (loss) income before income taxes, including noncontrolling interests		(7.9	)		11.4			—		3.5
Income tax benefit (expense)		1.5			(2.2	)		0.3		(0.4	)
Net (loss) income attributable to Enhabit	$	(6.4	)	$	9.2		$	0.3	$	3.1
Diluted earnings per share⁽⁴⁾	$	(0.13	)	$	0.18		$	0.01	$	0.06
Diluted shares		50.0								50.0

(1)	Reconciliation to GAAP provided below.
(2)	Unusual or nonrecurring items in Q4 2023 include costs associated with nonroutine litigation, the strategic review process and restructuring activities.
(3)	Income tax adjustments include revisions to the estimates of tax balances as of the Separation date and the effect of permanent book-tax differences attributable to stock-based compensation.
(4)	Diluted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share
	Three Months Ended December 31,
	2022
				Adjustments
	As Reported			Impairment of Goodwill			Unusual or nonrecurring items that are not typical of ongoing operations			Income Tax Adjustments⁽³⁾		As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA⁽¹⁾	$	30.3		$	—		$	—		$	—	$	30.3
Impairment of goodwill		(109.0	)		109.0			—			—		—
Interest expense and amortization of debt discounts & fees		(8.7	)		—			—			—		(8.7	)
Depreciation and amortization		(8.3	)		—			—			—		(8.3	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽²⁾		(2.5	)		—			2.5			—		—
Stock-based compensation		(2.1	)		—			—			—		(2.1	)
Net (loss) income before income taxes, including noncontrolling interests		(100.3	)		109.0			2.5			—		11.2
Income tax benefit (expense)		5.1			(13.7	)		(0.6	)		6.2		(3.0	)
Net (loss) income attributable to Enhabit	$	(95.2	)	$	95.3		$	1.9		$	6.2	$	8.2
Diluted earnings per share⁽⁴⁾	$	(1.91	)	$	1.91		$	0.05		$	0.12	$	0.17
Diluted shares		49.8											49.8

(1)	Reconciliation to GAAP provided below.
(2)	Unusual or nonrecurring items in Q4 2022 include one-time standalone transition costs and costs associated with nonroutine litigation.
(3)	Income tax adjustments include revisions to the estimates of tax balances as of the Separation date and the effect of permanent book-tax differences attributable to stock-based compensation.
(4)	Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share
	Year Ended December 31,
	2023
				Adjustments
	As Reported			Impairment of Goodwill			Unusual or nonrecurring items that are not typical of ongoing operations			Income Tax Adjustments⁽³⁾		As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA⁽¹⁾	$	97.6		$	—		$	—		$	—	$	97.6
Impairment of goodwill		(85.8	)		85.8			—			—		—
Interest expense and amortization of debt discounts & fees		(43.0	)		—			—			—		(43.0	)
Depreciation and amortization		(30.9	)		—			—			—		(30.9	)
Unusual or nonrecurring items that are not typical of ongoing operations ⁽²⁾		(21.2	)		—			21.2			—		—
Stock-based compensation		(8.9	)		—			—			—		(8.9	)
Gain on disposal or impairment of assets		0.3			—			—			—		0.3
Net (loss) income before income taxes, including noncontrolling interests		(91.9	)		85.8			21.2			—		15.1
Income tax benefit (expense)		11.4			(11.1	)		(5.1	)		0.9		(3.9	)
Net (loss) income attributable to Enhabit	$	(80.5	)	$	74.7		$	16.1		$	0.9	$	11.2
Diluted earnings per share⁽⁴⁾	$	(1.61	)	$	1.50		$	0.32		$	0.02	$	0.22
Diluted shares		49.9											49.9

(1)	Reconciliation to GAAP provided below.
(2)	Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation, restructuring activities, one-time standalone transition costs, shareholder activism and the strategic review process.
(3)	Income tax adjustments include revisions to the estimates of tax balances as of the Separation date and the effect of permanent book-tax differences attributable to stock-based compensation.
(4)	Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share
	Year Ended December 31,
	2022
				Adjustments
	As Reported			Impairment of Goodwill			Unusual or nonrecurring items that are not typical of ongoing operations			Income Tax Adjustments⁽³⁾		As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA⁽¹⁾	$	149.3		$	—		$	—		$	—	$	149.3
Impairment of goodwill		(109.0	)		109.0			—			—		—
Depreciation and amortization		(33.0	)		—			—			—		(33.0	)
Interest expense and amortization of debt discounts & fees		(15.0	)		—			—			—		(15.0	)
Unusual or nonrecurring items that are not typical of ongoing operations⁽²⁾		(9.5	)		—			9.5			—		—
Stock-based compensation		(9.2	)		—			—			—		(9.2	)
Stock-based compensation included in overhead allocation		(1.1	)		—			—			—		(1.1	)
Loss on disposal or impairment of assets		(0.1	)		—			—			—		(0.1	)
Net (loss) income before income taxes, including noncontrolling interests		(27.6	)		109.0			9.5			—		90.9
Income tax (expense) benefit		(12.8	)		(13.7	)		(2.4	)		6.2		(22.7	)
Net (loss) income attributable to Enhabit	$	(40.4	)	$	95.3		$	7.1		$	6.2	$	68.2
Diluted earnings per share⁽⁴⁾	$	(0.81	)	$	1.91		$	0.14		$	0.12	$	1.36
Diluted shares		49.7											49.7

(1)	Reconciliation to GAAP provided below.
(2)	Unusual or nonrecurring items in 2022 include one-time standalone transition costs and costs associated with nonroutine litigation.
(3)	Income tax adjustments include revisions to the estimates of tax balances as of the Separation date and the effect of permanent book-tax differences attributable to stock-based compensation.
(4)	Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Net Loss to Adjusted EBITDA
	Three Months Ended December 31,						For the Year Ended December 31,
		2023			2022			2023			2022
	($ in millions)
Net loss	$	(5.9	)	$	(94.7	)	$	(79.0	)	$	(38.3	)
Interest expense		12.3			8.7			43.0			15.0
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾		11.4			2.5			21.2			9.5
Depreciation and amortization		7.7			8.3			30.9			33.0
Stock-based compensation		1.7			2.1			8.9			9.2
Income tax (benefit) expense		(1.5	)		(5.1	)		(11.4	)		12.8
Net income attributable to noncontrolling interests		(0.5	)		(0.5	)		(1.5	)		(2.1	)
Impairment of goodwill		—			109.0			85.8			109.0
(Gain) loss on disposal or impairment of assets		—			—			(0.3	)		0.1
Stock-based compensation included in overhead allocation		—			—			—			1.1
Adjusted EBITDA	$	25.2		$	30.3		$	97.6		$	149.3

(1)

Unusual or nonrecurring items in Q4 2023 include costs associated with nonroutine litigation, the strategic review process and restructuring activities; FY 2023 include costs associated with nonroutine litigation, restructuring activities, one-time standalone transition costs, shareholder activism and the strategic review process; in 2022, these items include one-time standalone transition costs and costs associated with nonroutine litigation.

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA
	Three Months Ended December 31,						For the Year Ended December 31,
		2023			2022			2023			2022
	($ in millions)
Net cash provided by operating activities	$	2.8		$	4.1		$	48.4		$	80.1
Unusual or nonrecurring items not typical of ongoing operations⁽¹⁾		11.4			2.5			21.2			9.5
Interest expense excluding amortization of debt discounts and fees		11.2			8.7			40.9			15.0
Change in assets and liabilities, excluding derivative instruments		3.1			19.2			(11.9	)		29.2
Current portion of income tax (benefit) expense		(3.0	)		(3.3	)		0.2			17.1
Net income attributable to noncontrolling interests in continuing operations		(0.5	)		(0.5	)		(1.5	)		(2.1	)
Other		0.2			(0.4	)		0.3			(0.6	)
Stock-based compensation included in overhead allocation		—			—			—			1.1
Adjusted EBITDA	$	25.2		$	30.3		$	97.6		$	149.3

(1)

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow
	Three Months Ended December 31,						For the Year Ended December 31,
	($ in millions)
		2023			2022			2023			2022
Net cash provided by operating activities	$	2.8		$	4.1		$	48.4		$	80.1
Unusual or nonrecurring items not typical of ongoing operations⁽¹⁾		11.4			2.5			21.2			9.5
Other working capital adjustments, including accrued unusual or nonrecurring items		(2.5	)		(0.7	)		(4.2	)		(0.7	)
Distributions paid to noncontrolling interests of consolidated affiliates		(0.7	)		(0.3	)		(3.2	)		(1.2	)
Capital expenditures for maintenance		0.2			(1.4	)		(3.4	)		(4.5	)
Stock-based compensation included in overhead allocation		—			—			—			1.1
Adjusted free cash flow	$	11.2		$	4.2		$	58.8		$	84.3

(1)

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Gross Margin to Adjusted EBITDA Margin
	Three Months Ended December 31,				For the Year Ended December 31,
	2023		2022		2023		2022

Gross margin as a percentage of revenue	48.8	%	49.4	%	48.8	%	50.9	%
General and administrative expenses	(43.9	)%	(39.7	)%	(42.2	)%	(38.7	)%
Unusual or nonrecurring items that are not typical of ongoing operations⁽¹⁾	4.4	%	0.9	%	2.0	%	0.9	%
Stock-based compensation	0.6	%	0.8	%	0.8	%	1.1	%
Noncontrolling interests	(0.2	)%	(0.2	)%	(0.1	)%	(0.2	)%
Other income	—	%	0.3	%	—	%	(0.1	)%
Adjusted EBITDA Margin	9.7	%	11.5	%	9.3	%	13.9	%

(1)

FORWARD-LOOKING STATEMENTS

Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and healthcare professionals; potential disruptions or breaches of our or our vendors’, payors’, and other contract counterparties’ information systems; the outcome of litigation; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; our ability to control costs, particularly labor and employee benefit costs; and factors that affect the timing and options in our strategic review and, following our strategic review, consummating a strategic transaction on attractive terms or at all. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company’s website at http://investors.ehab.com.

Stock Quote

Last Trade:	US$7.46
Daily Change:	0.19 2.61
Daily Volume:	320,851
Market Cap:	US$375.090M

November 06, 2024 Enhabit Reports Third Quarter 2024 Financial Results August 06, 2024 Enhabit Reports Second Quarter 2024 Financial Results July 15, 2024 Enhabit Releases Certain Preliminary Second Quarter 2024 Results July 01, 2024 Enhabit Releases Investor Presentation Demonstrating Execution of Clear Growth Strategy and Path to Unlock Shareholder Value May 08, 2024 Enhabit Reports First Quarter 2024 Financial Results LOAD MORE NEWS

Featured Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE